U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H19N3O5S
Molecular Weight 365.404
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEFROXADINE

SMILES

COC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CCC=CC3)C2=O)C(O)=O

InChI

InChIKey=RDMOROXKXONCAL-UEKVPHQBSA-N
InChI=1S/C16H19N3O5S/c1-24-9-7-25-15-11(14(21)19(15)12(9)16(22)23)18-13(20)10(17)8-5-3-2-4-6-8/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1

HIDE SMILES / InChI
Molecular Formula C16H19N3O5S
Molecular Weight 365.404
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Cefroxadine is an antibiotic developed for the treatment of bacterial infectious diseases caused by gram-negative and gram-positive organisms. The information about drug status is unavailable and is supposed to be "discontinued", however it may be manufactured in Italy by Novartis.

Originator

Approval Year

Unknown
149124
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
ORASPOR

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
17.62 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/16137854/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
4.5 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7389422/
125 mg single, oral
dose: 125 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
7.7 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7389422/
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12.3 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7389422/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
7.6 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7069577/
212 mg single, oral
dose: 212 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
16 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7069577/
424 mg single, oral
dose: 424 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
28.8 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7069577/
847 mg single, oral
dose: 847 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
46.25 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/16137854/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
6.1 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7389422/
125 mg single, oral
dose: 125 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12.07 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7389422/
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
23.59 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7389422/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.55 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7069577/
50 mg single, intravenous
dose: 50 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFROXADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
10.1 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7069577/
212 mg single, oral
dose: 212 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
21.3 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7069577/
424 mg single, oral
dose: 424 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
44.4 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7069577/
847 mg single, oral
dose: 847 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/16137854/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
1.13 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7389422/
125 mg single, oral
dose: 125 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.85 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7389422/
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.92 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7389422/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.74 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7069577/
50 mg single, intravenous
dose: 50 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFROXADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.03 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7069577/
212 mg single, oral
dose: 212 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.03 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7069577/
424 mg single, oral
dose: 424 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.03 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7069577/
847 mg single, oral
dose: 847 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFROXADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
40 mg/kg 4 times / day multiple, oral
Studied dose
Dose: 40 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 40 mg/kg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7334585
unhealthy, CHILD
Health Status: unhealthy
Age Group: CHILD
Sex: unknown
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/7334585
Other AEs: Diarrhea...
Other AEs:
Diarrhea (mild, 3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7334585
250 mg 4 times / day multiple, oral
Studied dose
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6436182/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6436182/
Disc. AE: Oedema...
Other AEs: Diarrhoea...
AEs leading to
discontinuation/dose reduction:
Oedema (1 pt)
Other AEs:
Diarrhoea (2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/6436182/
AEs

AEs

AESignificanceDosePopulation
Diarrhea mild, 3 patients
40 mg/kg 4 times / day multiple, oral
Studied dose
Dose: 40 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 40 mg/kg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7334585
unhealthy, CHILD
Health Status: unhealthy
Age Group: CHILD
Sex: unknown
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/7334585
Oedema 1 pt
Disc. AE
250 mg 4 times / day multiple, oral
Studied dose
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6436182/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6436182/
Diarrhoea 2 patients
250 mg 4 times / day multiple, oral
Studied dose
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6436182/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6436182/
PubMed

PubMed

TitleDatePubMed
A specific and rapid HPLC assay for the determination of cefroxadine in human plasma and its application to pharmacokinetic study in Korean.
2006-02-13
[Antibacterial activity of oral cephems against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
2004-12
Patents

Patents

CN102267953 B
2
CN102268022 A
2
EP0953569 A1
2

Sample Use Guides

In Vivo Use Guide
The daily dosage of 1000mg should be divided into 2 fractions and should be taken after breakfast and after supper.
Route of Administration: Oral
In Vitro Use Guide
The spectrum of antibacterial activity of cefroxadine against gram-positive and gram-negative bacteria was studied. About 0.005 ml of diluted culture was inoculated by Micro-planter onto agar plates containing a series of serial twofold dilutions of a drug. The concentration of the drug required to inhibit the growth of 50% of the total number of tested E. coli strains (MIC50) was 3.13 to 6.25 ug/ml. The MIC50 of cefroxadine against K. pneumoniae strains was 3.13 to 6.25 ug/ml.
Substance Class Chemical
Created
by admin
on Wed Apr 02 07:03:28 GMT 2025
Edited
by admin
on Wed Apr 02 07:03:28 GMT 2025
Record UNII
B908C4MV2R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFROXADINE
INN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
CEFTHAN-DS
Preferred Name English
CEFROXADINE [MART.]
Common Name English
CEFROXADINE [MI]
Common Name English
cefroxadine [INN]
Common Name English
Cefroxadine [WHO-DD]
Common Name English
ORASPOR
Brand Name English
(6R,7R)-7-[(R)-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido]-3-methoxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Systematic Name English
CGP 9000
Code English
CGP-9000
Code English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-((AMINO-1,4-CYCLOHEXADIEN-1-YLACETYL)AMINO)-3-METHOXY-8-OXO-, (6R-(6A,7B(R*)))-
Systematic Name English
CEFROXADINE [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C357
Created by admin on Wed Apr 02 07:03:28 GMT 2025 , Edited by admin on Wed Apr 02 07:03:28 GMT 2025
WHO-ATC J01DB11
Created by admin on Wed Apr 02 07:03:28 GMT 2025 , Edited by admin on Wed Apr 02 07:03:28 GMT 2025
WHO-VATC QJ01DB11
Created by admin on Wed Apr 02 07:03:28 GMT 2025 , Edited by admin on Wed Apr 02 07:03:28 GMT 2025
Code System Code Type Description
MESH
C012671
Created by admin on Wed Apr 02 07:03:28 GMT 2025 , Edited by admin on Wed Apr 02 07:03:28 GMT 2025
PRIMARY
CHEBI
31379
Created by admin on Wed Apr 02 07:03:28 GMT 2025 , Edited by admin on Wed Apr 02 07:03:28 GMT 2025
PRIMARY
CAS
51762-05-1
Created by admin on Wed Apr 02 07:03:28 GMT 2025 , Edited by admin on Wed Apr 02 07:03:28 GMT 2025
PRIMARY
SMS_ID
100000081831
Created by admin on Wed Apr 02 07:03:28 GMT 2025 , Edited by admin on Wed Apr 02 07:03:28 GMT 2025
PRIMARY
ChEMBL
CHEMBL3186538
Created by admin on Wed Apr 02 07:03:28 GMT 2025 , Edited by admin on Wed Apr 02 07:03:28 GMT 2025
PRIMARY
FDA UNII
B908C4MV2R
Created by admin on Wed Apr 02 07:03:28 GMT 2025 , Edited by admin on Wed Apr 02 07:03:28 GMT 2025
PRIMARY
DRUG CENTRAL
557
Created by admin on Wed Apr 02 07:03:28 GMT 2025 , Edited by admin on Wed Apr 02 07:03:28 GMT 2025
PRIMARY
DRUG BANK
DB11367
Created by admin on Wed Apr 02 07:03:28 GMT 2025 , Edited by admin on Wed Apr 02 07:03:28 GMT 2025
PRIMARY
INN
4722
Created by admin on Wed Apr 02 07:03:28 GMT 2025 , Edited by admin on Wed Apr 02 07:03:28 GMT 2025
PRIMARY
MERCK INDEX
m3215
Created by admin on Wed Apr 02 07:03:28 GMT 2025 , Edited by admin on Wed Apr 02 07:03:28 GMT 2025
PRIMARY Merck Index
ECHA (EC/EINECS)
257-391-8
Created by admin on Wed Apr 02 07:03:28 GMT 2025 , Edited by admin on Wed Apr 02 07:03:28 GMT 2025
PRIMARY
EPA CompTox
DTXSID1022768
Created by admin on Wed Apr 02 07:03:28 GMT 2025 , Edited by admin on Wed Apr 02 07:03:28 GMT 2025
PRIMARY
EVMPD
SUB07419MIG
Created by admin on Wed Apr 02 07:03:28 GMT 2025 , Edited by admin on Wed Apr 02 07:03:28 GMT 2025
PRIMARY
NCI_THESAURUS
C81033
Created by admin on Wed Apr 02 07:03:28 GMT 2025 , Edited by admin on Wed Apr 02 07:03:28 GMT 2025
PRIMARY
WIKIPEDIA
Cefroxadine
Created by admin on Wed Apr 02 07:03:28 GMT 2025 , Edited by admin on Wed Apr 02 07:03:28 GMT 2025
PRIMARY
PUBCHEM
5284529
Created by admin on Wed Apr 02 07:03:28 GMT 2025 , Edited by admin on Wed Apr 02 07:03:28 GMT 2025
PRIMARY
Related Record Type Details
Structure of CEFROXADINE DIHYDRATE
SOLVATE->ANHYDROUS
Related Record Type Details
Structure of CEFROXADINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966